These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 27299483)

  • 1. Comparison of the exposure-response relationship of dapagliflozin in adult and paediatric patients with type 2 diabetes mellitus.
    Parkinson J; Tang W; Johansson CC; Boulton DW; Hamrén B
    Diabetes Obes Metab; 2016 Jul; 18(7):685-92. PubMed ID: 27299483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of dapagliflozin in children and adolescents with type 2 diabetes mellitus.
    Tirucherai GS; LaCreta F; Ismat FA; Tang W; Boulton DW
    Diabetes Obes Metab; 2016 Jul; 18(7):678-84. PubMed ID: 27291448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus.
    Tang W; Leil TA; Johnsson E; Boulton DW; LaCreta F
    Diabetes Obes Metab; 2016 Mar; 18(3):236-40. PubMed ID: 26510924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of pharmacokinetics and the exposure-response relationship of dapagliflozin between adolescent/young adult and adult patients with type 1 diabetes mellitus.
    Busse D; Tang W; Scheerer M; Danne T; Biester T; Sokolov V; Boulton D; Parkinson J
    Br J Clin Pharmacol; 2019 Aug; 85(8):1820-1828. PubMed ID: 31077437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary glucose excretion after dapagliflozin treatment: An exposure-response modelling comparison between Japanese and non-Japanese patients diagnosed with type 1 diabetes mellitus.
    Sokolov V; Yakovleva T; Ueda S; Parkinson J; Boulton DW; Penland RC; Tang W
    Diabetes Obes Metab; 2019 Apr; 21(4):829-836. PubMed ID: 30456904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
    Macha S; Mattheus M; Halabi A; Pinnetti S; Woerle HJ; Broedl UC
    Diabetes Obes Metab; 2014 Mar; 16(3):215-22. PubMed ID: 23859488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus.
    Kasichayanula S; Chang M; Hasegawa M; Liu X; Yamahira N; LaCreta FP; Imai Y; Boulton DW
    Diabetes Obes Metab; 2011 Apr; 13(4):357-65. PubMed ID: 21226818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetic- Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus.
    Mondick J; Riggs M; Kaspers S; Soleymanlou N; Marquard J; Nock V
    J Clin Pharmacol; 2018 May; 58(5):640-649. PubMed ID: 29251772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic profile of the sodium-glucose co-transporter-2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial.
    Laffel LMB; Tamborlane WV; Yver A; Simons G; Wu J; Nock V; Hobson D; Hughan KS; Kaspers S; Marquard J
    Diabet Med; 2018 Aug; 35(8):1096-1104. PubMed ID: 29655290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes Mellitus.
    Melin J; Tang W; Rekić D; Hamrén B; Penland RC; Boulton DW; Parkinson J
    J Clin Pharmacol; 2022 Oct; 62(10):1227-1235. PubMed ID: 35403243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects.
    Yang L; Li H; Li H; Bui A; Chang M; Liu X; Kasichayanula S; Griffen SC; Lacreta FP; Boulton DW
    Clin Ther; 2013 Aug; 35(8):1211-1222.e2. PubMed ID: 23910664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus.
    Hussey EK; Clark RV; Amin DM; Kipnes MS; O'Connor-Semmes RL; O'Driscoll EC; Leong J; Murray SC; Dobbins RL; Layko D; Nunez DJ
    J Clin Pharmacol; 2010 Jun; 50(6):623-35. PubMed ID: 20056803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Model-based characterization of the relationship between dapagliflozin systemic exposure and HbA1c response in patients with type 1 diabetes mellitus.
    Parkinson J; Tang W; Åstrand M; Melin J; Ekholm E; Hamrén B; Boulton DW
    Diabetes Obes Metab; 2019 Jun; 21(6):1381-1387. PubMed ID: 30756462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study.
    Sha S; Polidori D; Farrell K; Ghosh A; Natarajan J; Vaccaro N; Pinheiro J; Rothenberg P; Plum-Mörschel L
    Diabetes Obes Metab; 2015 Feb; 17(2):188-97. PubMed ID: 25421015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin.
    Kasichayanula S; Liu X; Griffen SC; Lacreta FP; Boulton DW
    Diabetes Obes Metab; 2013 Mar; 15(3):280-3. PubMed ID: 23061428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin.
    Ljunggren Ö; Bolinder J; Johansson L; Wilding J; Langkilde AM; Sjöström CD; Sugg J; Parikh S
    Diabetes Obes Metab; 2012 Nov; 14(11):990-9. PubMed ID: 22651373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.
    Kasichayanula S; Liu X; Lacreta F; Griffen SC; Boulton DW
    Clin Pharmacokinet; 2014 Jan; 53(1):17-27. PubMed ID: 24105299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dapagliflozin twice daily or once daily: effect on pharmacokinetics and urinary glucose excretion in healthy subjects.
    Tang W; Reele S; Hamer-Maansson JE; Parikh S; de Bruin TW
    Diabetes Obes Metab; 2015 Apr; 17(4):423-5. PubMed ID: 25511685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fed and Fasted Single-dose Assessment of Bioequivalence of Dapagliflozin and Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects.
    Boulton DW; Chang M; Griffen SC; Kitaura C; Lubin S; Pollack A; LaCreta F
    Clin Ther; 2016 Jan; 38(1):99-109. PubMed ID: 26682500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
    Mathieu C; Ranetti AE; Li D; Ekholm E; Cook W; Hirshberg B; Chen H; Hansen L; Iqbal N
    Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.